During the past decade, The Center for Rheumatology and Bone Research conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 38 clinical trials were completed, i.e. on average, 122.6% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 25 clinical trials were completed. i.e. 277.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Center for Rheumatology and Bone Research" #1 sponsor was "Pfizer" with 17 trials, followed by "Savient Pharmaceuticals" with 4 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored, "Horizon Therapeutics Ireland DAC" with 3 trials sponsored and "R-Pharm International, LLC" with 3 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Center for Rheumatology and Bone Research" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "Affibody" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Columbia University" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "The Center for Rheumatology and Bone Research" are "Rheumatoid Arthritis" (17 trials), "Osteoarthritis" (9 trials), "Arthritis, Rheumatoid" (8 trials), "Gout" (6 trials) and "Arthritis" (5 trials). Many other conditions were trialed in "The Center for Rheumatology and Bone Research" in a lesser frequency.

Most popular intervention types in "The Center for Rheumatology and Bone Research" are "Drug" (52 trials), "Biological" (18 trials), "Other" (9 trials), "Dietary Supplement" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Adalimumab" (4 trials), "Methotrexate" (4 trials), "Pegloticase" (4 trials) and "placebo" (4 trials). Other intervention names were less common.

The vast majority of trials in "The Center for Rheumatology and Bone Research" are 68 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "The Center for Rheumatology and Bone Research". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 55 completed trials in The Center for Rheumatology and Bone Research, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in The Center for Rheumatology and Bone Research, 0 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 2 trials that are defined as “Not Applicable".